Planning Directions Inc. Acquires Shares of 96,107 Pfizer Inc. (NYSE:PFE)

Planning Directions Inc. acquired a new stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 96,107 shares of the biopharmaceutical company's stock, valued at approximately $2,435,000. Pfizer accounts for about 1.0% of Planning Directions Inc.'s investment portfolio, making the stock its 23rd biggest holding.

Other institutional investors also recently bought and sold shares of the company. Bessemer Group Inc. grew its holdings in shares of Pfizer by 11.1% during the first quarter. Bessemer Group Inc. now owns 132,478 shares of the biopharmaceutical company's stock valued at $3,358,000 after buying an additional 13,228 shares during the last quarter. CHURCHILL MANAGEMENT Corp purchased a new stake in shares of Pfizer during the 1st quarter valued at about $8,283,000. Alta Advisers Ltd lifted its stake in shares of Pfizer by 69.6% in the 1st quarter. Alta Advisers Ltd now owns 31,912 shares of the biopharmaceutical company's stock worth $809,000 after purchasing an additional 13,100 shares during the period. WCM Investment Management LLC boosted its holdings in shares of Pfizer by 8.7% in the first quarter. WCM Investment Management LLC now owns 125,964 shares of the biopharmaceutical company's stock worth $3,176,000 after buying an additional 10,051 shares during the last quarter. Finally, Sage Mountain Advisors LLC grew its position in Pfizer by 7.3% during the fourth quarter. Sage Mountain Advisors LLC now owns 20,587 shares of the biopharmaceutical company's stock valued at $546,000 after buying an additional 1,404 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Stock Up 0.5%

Shares of NYSE:PFE opened at $25.45 on Monday. The company has a market capitalization of $144.66 billion, a PE ratio of 18.44, a P/E/G ratio of 0.92 and a beta of 0.58. The firm has a 50 day simple moving average of $23.72 and a 200-day simple moving average of $24.81. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.67 by $0.25. The firm had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. Pfizer had a return on equity of 20.33% and a net margin of 12.62%. The firm's revenue for the quarter was down 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.82 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Investors of record on Friday, July 25th will be given a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 annualized dividend and a dividend yield of 6.76%. Pfizer's dividend payout ratio is presently 124.64%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on PFE shares. Jefferies Financial Group lifted their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock a "buy" rating in a research note on Wednesday, May 21st. Redburn Atlantic dropped their price objective on shares of Pfizer from $29.00 to $27.00 and set a "neutral" rating for the company in a research note on Wednesday, April 30th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Bank of America increased their target price on shares of Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a research report on Wednesday, April 30th. Finally, Wolfe Research upped their price objective on shares of Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a report on Wednesday, April 30th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, six have issued a buy rating and three have given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $28.55.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.